<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, pathogenesis, and genetics of Parkinson disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, pathogenesis, and genetics of Parkinson disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, pathogenesis, and genetics of Parkinson disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Jankovic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parkinson disease (PD) is the leading cause of parkinsonism, a syndrome manifested by rest tremor, rigidity, bradykinesia, and postural instability. PD is one of the most common neurodegenerative diseases of adulthood and a major cause of neurologic morbidity and mortality worldwide.
        </p>
        <p>
         The clinical features of PD arise partly from progressive degeneration of dopamine-producing neurons in the basal ganglia, including the substantia nigra in the midbrain, but degeneration of nondopaminergic neurons is implicated in many motor and nonmotor symptoms. Thus, dopamine depletion and loss of other neurotransmitters account for the classic motor phenotype as well as a wide range of nonmotor and neuropsychiatric manifestations that affect function and quality of life.
        </p>
        <p>
         The cause or etiologic trigger of neurodegeneration in PD is still unknown in the majority of cases. However, remarkable progress has been fueled by discoveries about the anatomy and function of the basal ganglia, improved characterization of neuropathologic and neurochemical abnormalities, and studies of genetic and experimental forms of parkinsonism [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will review the epidemiology, pathology, pathogenesis, and genetics of PD. The clinical features, diagnosis, and treatment of PD are reviewed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">
          "Cognitive impairment and dementia in Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">
          "Management of nonmotor symptoms in Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4899.html" rel="external">
          "Nonpharmacologic management of Parkinson disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97581.html" rel="external">
          "Palliative approach to Parkinson disease and parkinsonian disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H492688052">
         <span class="h1">
          HISTORICAL CONTEXT
         </span>
         <span class="headingEndMark">
          —
         </span>
         PD was first described by James Parkinson in his 1817 Essay on the Shaking Palsy. However, there is some evidence that a disease known as "kampavata," consisting of shaking (kampa) and lack of muscular movement (vata), existed in the ancient Indian medical system, Ayurveda, as long as 4500 years ago [
         <a href="#rid2">
          2
         </a>
         ]. The
         <em>
          Mucuna pruriens
         </em>
         plant was used in ancient times to treat the symptoms and was later discovered to contain levodopa [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The pathology of PD was not well understood until the early 20th century, when the German pathologist Frederick Lewy in 1912 reported neuronal cytoplasmic inclusions in a variety of brain regions. In 1919, Tretiakoff observed that the most critical abnormality in PD was the loss of neurons in the substantia nigra pars compacta (SNc) of the midbrain. In the 1950s, investigators discovered the importance of dopamine and its depletion from the basal ganglia as the key to understanding the pathophysiology and pathologic biochemistry of PD [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1253931702">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3079074765">
         <span class="h2">
          Incidence and prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         PD is a growing source of disability and mortality among neurologic disorders. The estimated prevalence is 94 cases per 100,000 people, or approximately 0.3 percent in the general population 40 years of age and older [
         <a href="#rid5">
          5,6
         </a>
         ]. The yearly incidence of new cases ranges from 8 to 18.6 per 100,000 person-years [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The incidence and prevalence of PD are rising. In the year 2016, the estimated global prevalence of PD was 6.1 million people, increased from 2.5 million in 1990 [
         <a href="#rid6">
          6
         </a>
         ]. A similar trend has been observed in age-adjusted mortality from PD [
         <a href="#rid8">
          8
         </a>
         ]. Although aging of the world population accounts for much of the increase in absolute numbers, the age-adjusted incidence is also rising, for reasons that are not fully understood.
        </p>
        <p class="headingAnchor" id="H3818202825">
         <span class="h2">
          Risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Age is the most important risk factor for PD. The incidence and prevalence rise steadily in adults beginning in the fifth decade [
         <a href="#rid5">
          5
         </a>
         ]. Nonetheless, PD is not solely a disease of older adults. Approximately 25 percent of people with PD are diagnosed before the age of 65 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex
         </strong>
         – Males have a higher risk of PD than females by a ratio of approximately 1.4:1 [
         <a href="#rid6">
          6
         </a>
         ]. However, a sex difference is not present in all studies, and in one meta-analysis, a significant difference in prevalence by sex was only present in the 50-to-59-year age group [
         <a href="#rid5">
          5
         </a>
         ]. Factors associated with lower lifetime estrogen exposure (eg, early menopause, higher parity) have been associated with increased PD risk in females [
         <a href="#rid9">
          9
         </a>
         ]. This effect has also been suggested by studies in females who have undergone premenopausal oophorectomy. (See
         <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">
          "Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Cognitive function and neurologic disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – A family history of PD in a first-degree relative is associated with a two- to threefold increase in the risk of PD [
         <a href="#rid10">
          10
         </a>
         ]. Monogenic forms of PD account for less than 10 percent of PD cases and span autosomal dominant, autosomal recessive, and X-linked inheritance patterns. Most have a younger age of onset compared with sporadic PD. (See
         <a class="local">
          'Genetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aside from monogenic forms of PD, heterozygous pathogenic variants in the glucocerebrosidase 1 (
         <em>
          GBA1
         </em>
         ) gene are another important genetic risk factor for PD. Other lysosomal enzyme-encoding genes have also been found to alter risk. (See
         <a class="local">
          'Glucocerebrosidase gene'
         </a>
         below and
         <a class="local">
          'Other lysosomal genes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Environmental exposures
         </strong>
         – A large number of environmental exposures have been identified as risk factors for PD in epidemiologic studies. Examples include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposure to pesticides [
         <a href="#rid10">
          10-17
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposure to air pollution, including nitrogen dioxide and fine particulate matter [
         <a href="#rid18">
          18,19
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High consumption of dairy products [
         <a href="#rid20">
          20,21
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Living in urban or industrial areas with high release of copper, manganese, or lead [
         <a href="#rid22">
          22
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposure to hydrocarbon solvents, particularly trichloroethylene [
         <a href="#rid23">
          23,24
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Living in rural areas [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Farming or agriculture work [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of well water [
         <a href="#rid10">
          10,25
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High dietary intake of iron, especially in combination with high manganese intake [
         <a href="#rid26">
          26
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced levels of dietary and sunlight-derived vitamin D [
         <a href="#rid27">
          27-29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Paradoxically, other data suggest that mortality from PD is increased among people with higher socioeconomic occupations (eg, education, computer and mathematical, legal, architecture and engineering) where exposure to toxins is unlikely, while PD mortality is decreased among people with lower socioeconomic occupations (eg, mining and drilling, transportation and material moving, construction) where exposure to toxins is more likely [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidities
         </strong>
         – A variety of medical and psychiatric illnesses in early or mid-life have been associated with increased risk of PD in observational studies. Among the most consistently identified risk factors are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Excess body weight and metabolic syndrome [
         <a href="#rid32">
          32,33
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type 2 diabetes mellitus [
         <a href="#rid34">
          34-36
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of traumatic brain injury [
         <a href="#rid37">
          37-39
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of melanoma or prostate cancer [
         <a href="#rid40">
          40-45
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A number of reports, including several large population-based case-control studies, have found an association between depression and the subsequent development of PD [
         <a href="#rid46">
          46-51
         </a>
         ]. These findings suggest that depression is either a risk factor for PD or a prodromal symptom of PD. Similarly, meta-analyses of observational studies suggest a preceding history of constipation is either an early manifestation of PD or a risk factor for PD [
         <a href="#rid10">
          10,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H298349000">
         <span class="h2">
          Protective factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most consistently identified negative associations, or protective factors, for PD are cigarette smoking, caffeine consumption, and physical exercise. A variety of medications and classes of medications have been identified as potentially protective in observational studies, but none has yet borne out in prospective trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking
         </strong>
         – An inverse correlation between PD and smoking is supported by the findings of large cohort studies and meta-analyses [
         <a href="#rid1">
          1,10,53-56
         </a>
         ]. In a meta-analysis of 26 observational studies, the risk of PD was more than twofold lower for current smokers compared with never smokers (relative risk [RR] 0.44, 95% CI 0.39-0.50) [
         <a href="#rid10">
          10
         </a>
         ]. In addition, the risk of PD was lower for ever smokers compared with never smokers (RR 0.64, 95% CI 0.60-0.69). A neuroprotective effect of nicotine has been proposed as one possible explanation for these observations [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative hypothesis is that patients who develop PD are less likely to smoke in the first place, or are more likely to quit smoking, than those who do not develop PD. This alternative explanation posits that since dopamine is an integral component of the brain's reward system, people who will later develop signs of PD do not engage in reward-seeking behaviors, such as smoking, because dopamine is significantly depleted in the basal ganglia years before symptoms of PD appear [
         <a href="#rid58">
          58-60
         </a>
         ]. Others hypothesize that the tendency to smoke represents a risk-taking behavior, and that general risk tolerance as a genetically determined trait is causally related to PD [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Caffeine
         </strong>
         – Coffee and caffeine intake have been associated with lower risk of PD in meta-analyses and large cohort studies [
         <a href="#rid10">
          10,55,62,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise
         </strong>
         – Aerobic exercise and physical activity may be protective against development of PD [
         <a href="#rid64">
          64-66
         </a>
         ]. In a meta-analysis of eight prospective studies in more than 500,000 individuals, moderate to vigorous physical activity was associated with an approximately 30 percent reduction in the RR of PD [
         <a href="#rid67">
          67
         </a>
         ]. However, an alternative explanation for the association is reversed causality, given that reduced physical activity may be a preclinical sign of PD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ibuprofen
         </strong>
         – There is evidence from several meta-analyses that
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         may be associated with a reduced risk of PD [
         <a href="#rid68">
          68-71
         </a>
         ]. The data regarding other nonsteroidal anti-inflammatory drugs (NSAIDs) are conflicting, with some meta-analyses finding that NSAIDs are associated with a reduced risk of PD [
         <a href="#rid10">
          10,69
         </a>
         ] and others finding no significant association [
         <a href="#rid68">
          68,70,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – The relationship among statin use, lipid levels, and PD is unsettled despite numerous observational studies. Some meta-analyses suggest that statins are associated with a lower risk of PD [
         <a href="#rid72">
          72,73
         </a>
         ], while others conclude that the apparent protective effect of statin use is explained at least in part by failure to adjust for confounders [
         <a href="#rid74">
          74
         </a>
         ]. Yet other observational studies have found that statin use is associated with a higher risk of PD incidence and progression [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The available prospective data, although limited, do not support use of statins for the purpose of neuroprotection in PD. In a randomized trial among 235 patients with moderate PD associated with motor complications, motor scores at 24 months were nonsignificantly worse in the
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         arm compared with the placebo arm (1.52 points more deterioration, 80% CI -0.77 to 3.80) [
         <a href="#rid77">
          77
         </a>
         ]. By contrast, a smaller trial of
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         in patients with early-stage PD found a nonsignificant, approximately 3-point improvement in motor scores at 48 weeks compared with placebo, which lessened after a washout period, suggesting possible symptomatic rather than neuroprotective effects [
         <a href="#rid78">
          78
         </a>
         ]. Larger studies are needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycolysis-enhancing drugs
         </strong>
         –
         <a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">
          Terazosin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9105" href="/z/d/drug information/9105.html" rel="external">
          alfuzosin
         </a>
         are alpha-1-adrenergic receptor antagonists used to treat hypertension and benign prostatic hyperplasia that bind to phosphoglycerate kinase 1 (PGK1) and increase energy metabolism. In cellular and animal models, enhancing glycolysis reduces PD progression [
         <a href="#rid79">
          79
         </a>
         ]. In several large database studies, use of terazosin, doxazosin, or alfuzosin has been associated with reduced risk of PD or PD progression compared with nonuse or use of
         <a class="drug drug_general" data-topicid="9654" href="/z/d/drug information/9654.html" rel="external">
          tamsulosin
         </a>
         , an alpha-1-adrenergic receptor antagonist that does not have PGK1 activity [
         <a href="#rid79">
          79-81
         </a>
         ]. Further studies are needed to explore a possible protective effect prospectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhibitors of the renin-angiotensin system
         </strong>
         – Preclinical studies suggest that activation of the renin-angiotensin system may promote neurodegeneration in PD via pro-oxidative and/or proinflammatory effects; there is corresponding interest in angiotensin receptor blockers as a neuroprotective strategy [
         <a href="#rid82">
          82,83
         </a>
         ]. In several retrospective cohort studies, use of an angiotensin receptor blocker has been associated with lower risk of incident PD compared with nonuse [
         <a href="#rid84">
          84-86
         </a>
         ]. Clinical trials are needed to further explore these associations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The central defect in PD is dopamine depletion from the basal ganglia. This results in major disruptions in the connections to the thalamus and motor cortex and results in the classic parkinsonian signs of bradykinesia and rigidity.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Basal ganglia circuits
         </span>
         <span class="headingEndMark">
          —
         </span>
         The basal ganglia, sometimes referred to as the extrapyramidal system, include the substantia nigra, striatum (caudate and putamen), globus pallidus (GP), subthalamic nucleus (STN), and thalamus.
        </p>
        <p>
         The cortical input to the basal ganglia from the prefrontal supplementary motor area, amygdala, and hippocampus is excitatory, mediated by the neurotransmitter glutamate. Neurons in the substantia nigra pars compacta (SNc) provide major dopaminergic input to the striatum and exert both excitatory and inhibitory influences on the striatal output neurons. The interaction between the afferent and efferent pathways is mediated by striatal interneurons, which utilize acetylcholine as the main neurotransmitter.
        </p>
        <p>
         The striatal output system is mediated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The connection between the STN and the internal (medial) globus pallidus (GPi) and between STN and the external (lateral) globus pallidus (GPe) is excitatory, mediated by glutamate.
        </p>
        <p>
         Five distinct dopamine receptors (D1 through D5) have been cloned and characterized; they are found throughout the basal ganglia and limbic system. The D1 and D2 receptors are highly concentrated in the dorsal (motor) striatum and are the most relevant to the pathophysiology of PD because they are activated by the dopaminergic pathway originating in the SNc and terminating in the caudate and putamen. Receptors designated as D3, D4, and D5 are more abundant in the mesolimbic or emotional part of the brain (D3, D4) and hippocampus/hypothalamus (D5) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         Dopamine deficiency in the nigrostriatal pathway, such as that seen in PD, causes denervation hypersensitivity of D1 and D2 receptors [
         <a href="#rid88">
          88
         </a>
         ]. When compared with normal matched controls, D2 receptors in the dorsal putamen are increased by 15 percent in patients with PD, whereas D3 receptors in the mesolimbic system are decreased by 40 to 45 percent [
         <a href="#rid89">
          89
         </a>
         ]. These results may explain the basis for the hypersensitivity of the nigrostriatal (D2) dopaminergic receptors that is observed in PD.
        </p>
        <p>
         There are two output pathways from the striatum  (
         <a class="graphic graphic_figure graphicRef82136" href="/z/d/graphic/82136.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The indirect pathway is mediated chiefly via dopamine's inhibitory influence on striatal D2 dopamine receptors. In the indirect pathway, the striatum projects to the neurons in the GPe utilizing GABA, and the GPe in turn projects to the STN, which provides excitatory input via glutamate to the GPi and substantia nigra pars reticulata (SNr). GPi neurons are GABA-ergic and synapse in the ventrolateral nucleus of the thalamus. Thalamic input to the cortex is excitatory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The direct pathway is mediated via dopamine's excitatory influence on striatal D1 dopamine receptors. In the direct pathway, the striatum projects directly to the GPi and SNr.
        </p>
        <p>
        </p>
        <p>
         In PD, a reduction of dopamine-producing neurons from the normal complement of approximately 550,000 to the critically low level of 100,000 leads to dopamine depletion in the substantia nigra and in the nigrostriatal pathway to the caudate and putamen. This, in turn, results in relative overactivity of the indirect pathway, functionally disinhibiting the STN. Decreased inhibition of the direct pathway causes additional disinhibition of the output nuclei (GPi and SNr). Increased output from GPi causes increased inhibition of the thalamus and reduced excitatory input to the motor cortex, which is ultimately expressed as bradykinesia and other parkinsonian signs.
        </p>
        <p>
         In PD, synchronized oscillatory activity in the 10 to 50 Hz band (often termed the beta-band), prevalent in the basal ganglia thalamocortical circuit, may be important in mediating certain parkinsonian features, including bradykinesia and tremor, and can be reduced by dopaminergic treatments [
         <a href="#rid90">
          90
         </a>
         ]. Therefore, surgical treatments for PD, such as lesion placement within or stimulation of GPi or STN, may act by desynchronizing the oscillatory basal ganglia-thalamo-cortical network activity.
        </p>
        <p>
         Models of basal ganglia dysfunction  (
         <a class="graphic graphic_figure graphicRef82136" href="/z/d/graphic/82136.html" rel="external">
          figure 1
         </a>
         ) are useful for conceptualizing how the motor symptoms of PD arise. However, the actual pathophysiology of the basal ganglia associated with PD is much more complex than indicated by these models [
         <a href="#rid91">
          91
         </a>
         ]. Existing models should be constantly re-evaluated as new findings become available.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Compensatory mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The brain has a remarkable capacity to compensate for the presynaptic dopamine depletion by increasing the synthesis of dopamine in surviving neurons and by increasing the afferents to the dendrites of dopaminergic neurons. Dopaminergic denervation also results in a proliferation of D2 receptors, as well as a colocalization of D1 and D2 receptors [
         <a href="#rid92">
          92
         </a>
         ]. Similarly, gap junctions, which allow rapid communications between striatal neurons, increase dramatically after dopaminergic denervation [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         In the brains of patients with PD, the number of tyrosine hydroxylase-staining neurons in the striatum is markedly decreased [
         <a href="#rid94">
          94
         </a>
         ]. Since tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine, is still present in surviving neurons, the synthesis of dopamine could be increased in these striatal neurons, thereby compensating for the presynaptic dopamine loss [
         <a href="#rid95">
          95,96
         </a>
         ]. Another compensatory mechanism may be downregulation of the dopamine transporter, resulting in less dopamine reuptake and higher synaptic dopamine levels [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
         Three stages of compensation during the presymptomatic period of PD have been proposed [
         <a href="#rid96">
          96
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An early period during which the dopamine homeostatic compensatory mechanisms discussed above are capable of "masking" the disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased activity of the basal ganglia output nuclei (eg, the GPi) as striatal dopamine homeostasis breaks down
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intensity of compensation in structures outside of the basal ganglia (eg, supplementary motor area of the cortex) as parkinsonian motor abnormalities emerge
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The brains of patients with PD typically show depigmentation, neuronal loss, and gliosis, particularly in the substantia nigra pars compacta (SNc) and in the pontine locus ceruleus. Neuronal degeneration is also present in the dorsal nucleus of the vagus in the medulla and other brainstem nuclei.
        </p>
        <p class="headingAnchor" id="H2720692707">
         <span class="h2">
          Key sites of neuronal loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ventrolateral portion of the substantia nigra that projects to the dorsal putamen is preferentially affected early in the course of PD, resulting in the gradual loss of dopaminergic neurons in the SNc and a nearly complete depletion of dopamine, particularly in the putamen [
         <a href="#rid98">
          98
         </a>
         ]. This contrasts with normal aging, which is usually associated with neuronal loss in the dorsal tier of the SNc, and depletion of dopamine, predominantly in the caudate nucleus [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         In otherwise healthy adults, there are approximately 550,000 pigmented neurons and 260,000 nonpigmented neurons in the substantia nigra [
         <a href="#rid100">
          100
         </a>
         ]. By the time the first symptoms of PD emerge, approximately 60 percent of the neurons in the SNc have been lost [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Because of the apparent discrepancy between loss of striatal dopamine (&gt;80 percent) and the degree of loss of neurons in the substantia nigra (50 to 60 percent), some have suggested that the initial site of pathology is in the striatum and that retrograde degeneration may be responsible for the neuronal loss in the substantia nigra [
         <a href="#rid4">
          4
         </a>
         ]. An alternative explanation is that each dopaminergic neuron has multiple projections that terminate in the striatum, so that death of the cell body has a multiplying effect on loss of terminals.
        </p>
        <p>
         In addition to the degeneration of the SNc, other nuclei are affected by the pathology of PD, including the internal (medial) globus pallidus (GPi), the center median-parafascicular complex, the pedunculopontine tegmental nucleus, and the glutamatergic caudal intralaminar thalamic nuclei [
         <a href="#rid101">
          101
         </a>
         ]. Moreover, volumetric magnetic resonance imaging (MRI) studies have found significant hippocampal atrophy in patients with PD, with or without cognitive impairment [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Lewy bodies and other intracellular inclusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus as to what pathologic criteria are necessary for the diagnosis of PD [
         <a href="#rid1">
          1
         </a>
         ], but most investigators believe that Lewy bodies, named for Frederick Lewy, constitute the pathologic hallmark of PD.
        </p>
        <p>
         Lewy bodies are round, eosinophilic, intracytoplasmic neuronal inclusions. They are 3 to 25 nm in diameter with a dense granular core (1 to 8 nm) and loosely arranged fibrillary elements extending towards a peripheral "halo." Immunohistochemical studies have demonstrated that Lewy bodies are made up mainly of alpha-synuclein and ubiquitin and also contain calbindin, synphilin-1, complement proteins, microfilament subunits, tubulin, microtubule-associated protein 1 and 2, and a parkin substrate protein called Pael-R [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p>
         In patients with PD, Lewy bodies are seen in the substantia nigra, the basal nucleus of Meynert, the locus ceruleus, the cerebral cortex, the sympathetic ganglia, the dorsal vagal nucleus, the myenteric plexus of the intestines, and even in the cardiac sympathetic plexus. Lewy bodies appear to arise from the peripheral portion of other inclusions known as pale bodies, which are found in the substantia nigra and locus ceruleus [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         Lewy bodies are not specific for PD since they are found in as many as 10 percent of brains of otherwise healthy older adults, as well as in patients with other neurodegenerative diseases, such as neurodegeneration with brain iron accumulation (NBIA), ataxia-telangiectasia, progressive supranuclear palsy, corticobasal degeneration, Down syndrome, and Alzheimer disease. There is growing evidence that Lewy bodies occur not only in synucleinopathies such as PD or amyloidopathies such as Alzheimer disease, but also in tauopathies, such as frontotemporal dementia [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         The lack of specificity of the pathologic findings raises the possibility that PD may not be a specific disease entity, but rather a clinically prototypical syndrome with different clinical subtypes and pathogenic causes  (
         <a class="graphic graphic_table graphicRef80669" href="/z/d/graphic/80669.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         Inclusions such as Lewy bodies have traditionally been considered toxic. However, some studies suggest that they may actually be neuroprotective and that compounds that promote the formation of inclusions lessen the pathology of PD [
         <a href="#rid105">
          105,108
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Braak staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the traditional view, the pathologic process of PD starts with degeneration of dopaminergic neurons in the substantia nigra. This view has been challenged by the neuropathologist Heiko Braak, who has proposed that the pathologic changes of PD start in the medulla of the brainstem and in the olfactory bulb, progressing rostrally over many years to the cerebral cortex in a predictable six-stage process  (
         <a class="graphic graphic_figure graphicRef69456" href="/z/d/graphic/69456.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid109">
          109,110
         </a>
         ].
        </p>
        <p>
         According to Braak staging, the progression of pathologic changes occurs as follows [
         <a href="#rid109">
          109
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During presymptomatic stages 1 and 2, the pathologic changes are found in the medulla oblongata and olfactory bulb.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In stages 3 and 4, the pathology has migrated rostrally to the SNc and other neuronal clusters of the midbrain and basal forebrain, at which time the classic motor symptoms of PD first appear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In end-stages 5 and 6, the pathologic process encroaches upon the telencephalic cortex of the temporal and frontal lobes.
        </p>
        <p>
        </p>
        <p>
         However, the validity and predictive utility of Braak staging has been questioned, as there are no cell counts to correlate with the described synuclein pathology and no observed asymmetry in the pathologic findings that correlate with the well-recognized asymmetry of clinical findings [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
         In addition, there is controversy as to the classification of dementia with Lewy bodies (DLB), considered by some to be a separate entity from PD. Braak did not include DLB in his observations on the progression of PD. (See
         <a class="medical medical_review" href="/z/d/html/5087.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5088.html" rel="external">
          "Clinical features and diagnosis of dementia with Lewy bodies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PATHOGENESIS OF CELL DEGENERATION
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Alpha-synuclein misfolding, aggregation, and toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alpha-synuclein is abundant in the central nervous system (CNS), accounting for 1 percent of total CNS protein. Its physiologic role is not fully understood, though it appears to be involved in synaptic function and plasticity [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
         An aggregated and insoluble form of alpha-synuclein is a major component of Lewy bodies, intracellular inclusions that are the pathologic hallmark of PD [
         <a href="#rid114">
          114
         </a>
         ]. Alpha-synuclein aggregates are a prominent finding in PD and several other neurodegenerative disorders (eg, dementia with Lewy bodies [DLB], multiple system atrophy), together known as synucleinopathies [
         <a href="#rid1">
          1,115
         </a>
         ].
        </p>
        <p>
         The mechanisms by which alpha-synuclein aggregates cause toxicity in PD are not well understood. However, insights have been gained through study of a monogenic form of PD caused by pathogenic variants in the synuclein alpha
         <em>
          (SNCA
         </em>
         ) gene.
         <em>
          SNCA
         </em>
         variants may cause the natively unfolded alpha-synuclein protein to alter its secondary structure and self-aggregate after being targeted for proteasomal degradation by ubiquitin [
         <a href="#rid116">
          116
         </a>
         ]. Misfolding of proteins and subsequent formation of insoluble aggregates can occur due to genetic variants that result in abnormal structure of the gene product, or as a result of age-related phenomena [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
         The hydrophobic portion of alpha-synuclein can spontaneously form fibrillar protein aggregates, and
         <em>
          SNCA
         </em>
         variants may promote the development of these aggregates [
         <a href="#rid118">
          118
         </a>
         ]. Furthermore, alpha-synuclein protoaggregates or oligomers can disrupt cell membranes, including dopamine vesicles and mitochondria, possibly by causing pores in the membranes [
         <a href="#rid118">
          118
         </a>
         ]. A protofibrillar form of alpha-synuclein appears to be more toxic than the normal or fibrillar form.
        </p>
        <p>
         Observations in transgenic and normal mice and in humans suggest that misfolded forms of alpha-synuclein can somehow be transmitted from diseased neurons to healthy ones [
         <a href="#rid119">
          119
         </a>
         ]. In normal mice, a single injection of synthetic misfolded alpha-synuclein fibrils into the striatum leads to cell-to-cell transmission of pathologic alpha-synuclein and Lewy body-like pathology with progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and impaired motor coordination [
         <a href="#rid120">
          120,121
         </a>
         ]. Pathologic alpha-synuclein appears to act as a template that corrupts normal alpha-synuclein, so it too becomes pathologic and thereby spreads the disease from an affected neuron to a normal one, which in turn becomes diseased.
        </p>
        <p>
         Further suggestion of cell-to-cell spread is provided by long-term study of patients with PD who received human fetal nigral neuron transplantation. At autopsy, grafted nigral neurons have been found to contain Lewy bodies that stain positive for alpha-synuclein [
         <a href="#rid122">
          122,123
         </a>
         ].
        </p>
        <p>
         Several anti-synuclein strategies are being investigated in clinical trials as potential disease-modifying therapies [
         <a href="#rid124">
          124
         </a>
         ]. Results have been disappointing thus far, however. Trials of two different monoclonal antibodies directed at alpha-synuclein, cinpanemab and prasinezumab, in patients with early-stage PD each showed similar clinical and radiographic outcomes in the active treatment and placebo groups at 52 weeks [
         <a href="#rid125">
          125,126
         </a>
         ]. The cinpanemab trial also reported no clear differences at 104 weeks in a blinded extension phase, which was halted due to lack of efficacy [
         <a href="#rid125">
          125
         </a>
         ]. Studies of active immunotherapy (vaccination) directed against alpha-synuclein in earlier stages of development are ongoing [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p>
         It should be noted that the Braak hypothesis and the notion of aggregated synuclein as the primary pathogenic mechanism of neurodegeneration have been increasingly challenged. Some investigators have proposed that abnormal soluble oligomers and fibrils of alpha-synuclein that aggregate into Lewy bodies are merely byproducts and may actually serve a protective rather than toxic function [
         <a href="#rid129">
          129,130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Defective proteolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cellular protein homeostasis is normally maintained primarily by three coordinated pathways (molecular chaperones, the ubiquitin-proteasome system, and the autophagy-lysosomal pathway) that mediate the repair or removal of abnormal proteins [
         <a href="#rid131">
          131-134
         </a>
         ]. While the data are not entirely consistent, it appears that all three pathways are involved in the processing of alpha-synuclein. When these systems are inhibited or impaired, abnormal proteins such as mutated alpha-synuclein can misfold, aggregate, and clog the normal molecular traffic of the cell, leading to cell death.
        </p>
        <p>
         Of particular interest is the finding in mice that the proteins parkin, PTEN-induced kinase 1 (PINK1), and DJ-1 bind to each other to form a complex that promotes degradation of unfolded or misfolded proteins via the ubiquitin-proteasome system [
         <a href="#rid135">
          135
         </a>
         ]. This observation is notable because pathogenic variants of parkin (
         <em>
          PRKN
         </em>
         ),
         <em>
          PINK1
         </em>
         , and
         <em>
          DJ-1
         </em>
         (PARK7) are individually associated with autosomal recessive forms of PD. Furthermore, Atp13a2 deficiency can cause lysosomal dysfunction and enhance the accumulation and toxicity of alpha-synuclein in vitro [
         <a href="#rid132">
          132,136
         </a>
         ]. This finding may reflect the pathogenesis of neurodegeneration associated with loss-of-function ATPase cation transporting 13A2 (
         <em>
          ATP13A2
         </em>
         ) gene variants that cause an early-onset form of parkinsonism. (See
         <a class="local">
          'Genetics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Mitochondrial dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of mitochondria in the pathogenesis of PD was first suggested by discovery of the association between the
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         analog 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and parkinsonism [
         <a href="#rid137">
          137,138
         </a>
         ]. The oxidation of MPTP produces 1-methyl-4-phenylpyridium (MPP+), which is taken up by dopaminergic terminals, selectively inhibits mitochondrial complex I activity, disrupts calcium homeostasis, and induces endoplasmic reticulum stress, resulting in cell damage [
         <a href="#rid138">
          138,139
         </a>
         ].
        </p>
        <p>
         Direct evidence of mitochondrial dysfunction is supported by the finding that complex I activity is decreased by 32 to 38 percent in the substantia nigra of patients with sporadic PD [
         <a href="#rid140">
          140,141
         </a>
         ] and by the finding that mitochondrial membrane potential and intracellular adenosine triphosphate (ATP) levels are significantly decreased in skin fibroblasts of patients with PD who carry the leucine rich repeat kinase 2 (
         <em>
          LRRK2
         </em>
         ) G2019S mutation [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         The following cascade of intracellular events has been postulated to lead to neurodegeneration [
         <a href="#rid143">
          143,144
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A cellular insult (eg, oxidative stress, excitotoxicity, deoxyribonucleic acid [DNA] damage) increases cytosolic calcium and oxidative radicals and activates nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1), leading to the formation of poly(ADP-ribose) (PAR)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This leads to decreased mitochondrial membrane potential, which in turn opens mitochondrial permeability transition pores (PTP)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Release of nicotinamide adenine dinucleotide (NAD+) through the PTP leads to NAD+ depletion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Release of mitochondrial apoptosis-initiating factors promotes release of cytochrome c, which leads to activation of the "executioner" enzyme caspase and to apoptosis
        </p>
        <p>
        </p>
        <p>
         Mitochondrial toxicity in PD has been modeled in mice using the lipophilic pesticide, rotenone, which is a potent inhibitor of mitochondrial complex I [
         <a href="#rid145">
          145
         </a>
         ]. The rotenone model provides support for the theory that neurodegeneration results from an interaction between environmental exposure and mitochondrial dysfunction.
        </p>
        <p>
         Further evidence for the role of mitochondria in the pathogenesis of PD is provided by the increasing number of genes (such as
         <em>
          PINK1
         </em>
         ) coding for mitochondrial proteins and implicated in cellular protection against oxidative damage, which have been associated with the PD phenotype [
         <a href="#rid146">
          146,147
         </a>
         ]. (See
         <a class="local">
          'PINK1-associated PD'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Oxidative stress
         </span>
         <span class="headingEndMark">
          —
         </span>
         The oxidative stress hypothesis postulates that inappropriate production of reactive oxygen species leads to neurodegeneration [
         <a href="#rid141">
          141,148
         </a>
         ]. Dopamine is normally metabolized not only by monoamine oxidase-mediated enzymatic oxidation but also by auto-oxidation to neuromelanin.
        </p>
        <p>
         Intraneuronal neuromelanin appears to have a dual role [
         <a href="#rid149">
          149
         </a>
         ]. First, it may be neuroprotective, preventing toxic accumulation of metabolites of catechol amines and scavenging reactive metals, pesticides, and other oxidants. Second, dying neurons may release neuromelanin, leading to chronic inflammation.
        </p>
        <p>
         These metabolic pathways generate byproducts, including hydrogen peroxide, superoxide anions, and hydroxyradicals. Free radicals, through interaction with membrane lipids, cause toxic lipid peroxidation, which has been found to be increased in the substantia nigra of PD brains. The oxidative products may cause neurotoxicity and, therefore, may play an important role in the development of PD.
        </p>
        <p>
         It is possible that increased oxidative stress also contributes to misfolding of proteins. This notion is supported by the finding that nitric oxide, a free radical increased in the brains of patients with PD, attacks disulfide isomerase, an aggregation-preventing chaperone protein localized to the endoplasmic reticulum and normally responsible for unfolding and transport of proteins [
         <a href="#rid150">
          150
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24078938">
         <span class="h2">
          Iron metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elemental iron plays a critical role in oxidative metabolism, and it also serves as a cofactor in the synthesis of neurotransmitters [
         <a href="#rid151">
          151
         </a>
         ]. It is increased by approximately 50 percent in the substantia nigra of PD brains relative to controls [
         <a href="#rid152">
          152
         </a>
         ], suggesting that abnormal iron metabolism plays a pathologic role in the development of PD [
         <a href="#rid153">
          153
         </a>
         ].
        </p>
        <p>
         One study found that mice lacking the tau protein developed parkinsonism due to toxic iron accumulation and neuronal loss in the substantia nigra [
         <a href="#rid154">
          154
         </a>
         ]. In addition, loss of tau in neuronal culture caused intracellular iron retention. Brain-permeable iron chelators prevent experimentally induced degeneration of nigrostriatal dopamine neurons [
         <a href="#rid154">
          154,155
         </a>
         ]. However, in a randomized trial of 372 patients with newly diagnosed PD,
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          deferiprone
         </a>
         (an iron chelator) resulted in more rapid symptomatic progression and worsened functional scores compared with placebo despite decreasing nigrostriatal iron content by MRI [
         <a href="#rid156">
          156
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Immunologic and inflammatory mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunologic mechanisms have been implicated in the pathogenesis of PD [
         <a href="#rid157">
          157,158
         </a>
         ]. Supporting evidence comes from the finding of elevated levels of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin-1 beta, and interferon-gamma in patients with PD.
        </p>
        <p>
         The role of inflammatory processes in the pathogenesis of PD is further supported by the presence of activated microglia and T cells in the basal ganglia of postmortem brain tissue in patients and mouse models of PD [
         <a href="#rid159">
          159
         </a>
         ]. In addition, positron emission tomography (PET) studies using ligands against translocator protein 18 kilodalton (TSPO), a marker for neuroinflammation, support microglial activation in treated patients as well as possible peripheral immune cell infiltration in patients with de novo, untreated PD [
         <a href="#rid160">
          160,161
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3884181346">
         <span class="h2">
          Mechanisms of cell death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Irrespective of the initial trigger (etiology) of neuronal degeneration in PD, the pathogenesis of neurodegeneration probably involves either programmed cell death (apoptosis) or necrosis [
         <a href="#rid1">
          1,162-164
         </a>
         ].
        </p>
        <p>
         Apoptosis is characterized by condensation of cytoplasm and chromatin, DNA fragmentation, and cell fragmentation into apoptotic bodies, followed by lysosome-mediated phagocytosis. The other mechanism of cell death, called autophagy, is characterized by accumulation of autophagic vesicles (autophagosomes and autophagolysosomes) and also plays an important role in neurodegeneration in PD [
         <a href="#rid165">
          165
         </a>
         ].
        </p>
        <p>
         It has been suggested that only 0.5 percent of substantia nigra neurons in otherwise healthy brains are undergoing apoptosis, but this number is increased fourfold to 2 percent in those with PD. Some experimental models of PD suggest that apoptosis is the primary mechanism of substantia nigra neuronal degeneration in PD, but convincing evidence from careful neuropathologic studies is lacking [
         <a href="#rid166">
          166,167
         </a>
         ].
        </p>
        <p>
         Although the precise mechanisms of neurodegeneration in PD are not yet understood, they most likely involve a cascade of events that include interaction between genetic and environmental factors and abnormalities in protein processing, oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammation, immune regulation, glial-specific factors, lack of trophic factors, and other, as-yet unknown, mechanisms  (
         <a class="graphic graphic_figure graphicRef82386" href="/z/d/graphic/82386.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef72207" href="/z/d/graphic/72207.html" rel="external">
          figure 4
         </a>
         ).
        </p>
        <p>
         One of the hypotheses is that neurodegeneration in PD is due to disruption of intracellular vesicular transport as a result of destabilizing of microtubules [
         <a href="#rid168">
          168
         </a>
         ]. Another area of interest is the role of astrocytes in various neurodegenerative disorders [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p>
         Another hypothesis is that PD arises from an early environmental exposure that increases vulnerability to dopaminergic cell loss later in life. As an example, it is possible that prenatal or early postnatal exposure to certain dopaminergic neuronal toxins, such as the MPTP-like herbicide paraquat and the manganese-containing fungicide maneb, may reduce the number of dopamine neurons in the substantia nigra in early development and enhance vulnerability to these toxins when individuals are subsequently exposed in adulthood [
         <a href="#rid170">
          170
         </a>
         ]. This is consistent with the so-called "multiple-hit hypothesis."
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the majority of cases of PD appear to be sporadic, there is increasing evidence that genetic factors play a role in the pathogenesis of PD, particularly when the age at symptom onset is younger than 50 years [
         <a href="#rid171">
          171-173
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H479738428">
         <span class="h2">
          Monogenic forms of PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial forms of parkinsonism have historically been designated numerically (eg, PARK1 through PARK23) based on their order of phenotypic description and chromosomal localization. Autosomal dominant, autosomal recessive, and possible X-linked forms of PD have been identified. As the number of monogenic causes of parkinsonism has rapidly expanded, a classification based on clinical phenotype and the causative gene variant (eg, PARK-
         <em>
          SNCA
         </em>
         ) is replacing the older numeric PARK designations [
         <a href="#rid174">
          174,175
         </a>
         ].
        </p>
        <p>
         The reported frequency of monogenic forms of PD varies considerably across studies, depending on the genes tested, the racial and ethnic background of the cohort, and age at disease onset. In a population-based cohort in the United Kingdom that included analysis of four genes (
         <em>
          PRKN
         </em>
         ,
         <em>
          PINK1
         </em>
         ,
         <em>
          LRRK2
         </em>
         , and
         <em>
          SNCA
         </em>
         ) in over 2000 patients with PD, monogenic forms of PD accounted for 1.4 percent of all PD cases and approximately 3 percent of young-onset PD (≤50 years old at onset) [
         <a href="#rid176">
          176
         </a>
         ]. In a multicenter cross-sectional study of 953 patients with young-onset PD that included analysis of six relevant genes (including glucocerebrosidase), the mutation carrier frequency was 17 percent [
         <a href="#rid177">
          177
         </a>
         ].
        </p>
        <p>
         Several of the most important monogenic forms of PD are discussed in greater detail in the following sections.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          <i>
           SNCA
          </i>
          -associated PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          SNCA
         </em>
         gene missense mutations (PARK1) or multiplications (PARK4) are rare causes of autosomal dominant parkinsonism [
         <a href="#rid178">
          178
         </a>
         ]. The phenotype varies from classic PD to dementia with Lewy bodies (DLB) [
         <a href="#rid179">
          179-181
         </a>
         ].
        </p>
        <p>
         The mechanism of
         <em>
          SNCA
         </em>
         -associated neurodegeneration is not yet fully understood but is probably due to a toxic gain-of-function effect [
         <a href="#rid179">
          179
         </a>
         ]. As discussed above, there is evidence that impaired processing of alpha-synuclein leads to abnormal protein aggregation and misfolding, Lewy body formation, cellular oxidative stress, and energy depletion. (See
         <a class="local">
          'Alpha-synuclein misfolding, aggregation, and toxicity'
         </a>
         above.)
        </p>
        <p>
         The
         <em>
          SNCA
         </em>
         gene was the first to be associated with parkinsonism when a genome scan in the Greek-Italian Contursi kindred identified a genetic marker on chromosome 4q21-q23 linked to the PD phenotype [
         <a href="#rid182">
          182
         </a>
         ]. This finding led to the discovery of a mutation in the single base pair (Ala53Thr) of the
         <em>
          SNCA
         </em>
         gene, designated PARK1 in the hierarchy of genetic forms of PD [
         <a href="#rid182">
          182,183
         </a>
         ].
        </p>
        <p>
         In the Contursi kindred, the clinical features of the disease are similar to otherwise typical PD, except for younger age at onset (mean 46 years), greater cognitive decline, and more rapid progression, with a mean time from onset to death of nine years [
         <a href="#rid184">
          184-186
         </a>
         ]. The pattern of nigrostriatal degeneration with preservation of D2 receptors, as demonstrated by positron emission tomography (PET), is similar to that seen in sporadic PD.
        </p>
        <p>
         Subsequently, a second pathogenic variant in the
         <em>
          SNCA
         </em>
         gene involving an alanine-for-proline substitution at amino acid 30 (Ala30Pro) was found in a German family [
         <a href="#rid180">
          180
         </a>
         ], and a third variant involving a glutamic acid-to-lysine substitution at position 46 (E46K) was identified in a Spanish family [
         <a href="#rid181">
          181
         </a>
         ].
        </p>
        <p>
         With reports of additional families, the phenotype of PARK1 has expanded to include not only typical PD features but also dementia, hallucinations, central hypoventilation, orthostatic hypotension, myoclonus, and urinary incontinence, with pathologic involvement of the brainstem pigmented nuclei, hippocampus, and temporal neocortex. Thus, the clinical and pathologic features of families with
         <em>
          SNCA
         </em>
         pathogenic variants and parkinsonism overlap the features of multiple system atrophy and DLB.
        </p>
        <p>
         Similarly, overexpression of
         <em>
          SNCA
         </em>
         may lead to neurodegenerative disease with features that overlap those of PD, DLB, and multiple system atrophy, as observed in families with parkinsonism and whole-gene duplication or triplication of
         <em>
          SNCA
         </em>
         [
         <a href="#rid187">
          187
         </a>
         ]. Duplication of
         <em>
          SNCA
         </em>
         appears to be associated with late-onset parkinsonism and dysautonomia, while triplication (designated PARK4) leads to early-onset PD and dementia [
         <a href="#rid188">
          188
         </a>
         ].
         <em>
          SNCA
         </em>
         triplication was found in one large family with autosomal dominant, young-onset parkinsonism, dysautonomia, cardiac denervation, DLB, and glial cytoplasmic inclusions at autopsy, features typical of multiple system atrophy [
         <a href="#rid189">
          189
         </a>
         ].
        </p>
        <p>
         Mounting evidence supports the role of common
         <em>
          SNCA
         </em>
         polymorphisms in sporadic PD [
         <a href="#rid190">
          190-193
         </a>
         ]. In particular, several large genome-wide association studies (GWAS) in PD found that
         <em>
          SNCA
         </em>
         was a risk locus for PD [
         <a href="#rid192">
          192-195
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          <i>
           LRRK2
          </i>
          -associated PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common form of monogenic PD is PARK8, caused by variants in the
         <em>
          LRRK2
         </em>
         gene on chromosome 12p11.2-q13.1 [
         <a href="#rid196">
          196,197
         </a>
         ].
        </p>
        <p>
         The
         <em>
          LRRK2
         </em>
         gene product is a protein called dardarin (from the Basque word "dardara," meaning tremor) that probably functions as a cytoplasmic kinase involved in phosphorylation of proteins, such as alpha-synuclein and microtubule-associated protein tau [
         <a href="#rid198">
          198-200
         </a>
         ]. Dardarin is a large molecule, encoded by 51 exons and containing 2527 amino acids. This contrasts with the much smaller alpha-synuclein protein, which contains 140 amino acids.
        </p>
        <p>
         Dardarin is closely associated with a variety of membrane and vesicular structures, membrane-bound organelles, and microtubules, suggesting its role in vesicular transport and in membrane and protein turnover, including lysosomal degradation pathway.
        </p>
        <p>
         <em>
          LRRK2
         </em>
         -associated PD may account for a significant proportion of familial PD cases and a smaller proportion of sporadic PD cases. It is estimated to cause up to 8 percent of autosomal dominant PD in the Basque population and up to 50 percent of familial PD in people of North African and Middle Eastern origin [
         <a href="#rid199">
          199,201-204
         </a>
         ]. In addition,
         <em>
          LRRK2
         </em>
         variants have been found in 0.4 to 1.9 percent of patients with idiopathic PD [
         <a href="#rid205">
          205-209
         </a>
         ], although such cases could also be explained by reduced penetrance in familial disease [
         <a href="#rid202">
          202
         </a>
         ].
        </p>
        <p>
         Genetic screening studies suggest that the G2019S mutation, the most common of the
         <em>
          LRRK2
         </em>
         pathogenic variants, accounts for 3 to 13 percent of autosomal dominant PD in Europe [
         <a href="#rid178">
          178,203,210-212
         </a>
         ] and 10 to 18 percent of autosomal dominant PD in Ashkenazi Jews [
         <a href="#rid204">
          204,213
         </a>
         ]. The G2019S variant has also been identified in asymptomatic carriers, suggesting reduced or age-dependent penetrance [
         <a href="#rid202">
          202,211
         </a>
         ]. Evidence of age-dependent penetrance was found in a study of 19 families with the G2019S variant, in whom the cumulative incidence of PD at ages 60, 70, and 80 years was 15, 21, and 32 percent, respectively [
         <a href="#rid214">
          214
         </a>
         ].
        </p>
        <p>
         The
         <em>
          LRRK2
         </em>
         -associated PD phenotype is often, but not always, associated with late-onset (mean age 65 years) disease [
         <a href="#rid200">
          200,211,215-217
         </a>
         ]. However, the typical features of PD associated with
         <em>
          LRRK2
         </em>
         G2019S variants are indistinguishable from idiopathic PD [
         <a href="#rid186">
          186,209
         </a>
         ]. The course of the disease is relatively benign, usually presenting with unilateral hand or leg tremor without cognitive deficit. Patients respond well to levodopa and have a slower decline in motor function compared with patients without an
         <em>
          LRRK2
         </em>
         mutation [
         <a href="#rid218">
          218
         </a>
         ]. Several studies have suggested that patients with
         <em>
          LRRK2
         </em>
         -associated PD may have an increased risk of certain types of cancer compared with idiopathic PD and healthy controls, such as leukemia, colon cancer, and possibly breast cancer [
         <a href="#rid219">
          219-222
         </a>
         ].
        </p>
        <p>
         Other clinical phenotypes associated with
         <em>
          LRRK2
         </em>
         variants have included parkinsonism with dementia or amyotrophy or both, typical essential tremor, dysautonomia, familial progressive supranuclear palsy, familial multiple system atrophy, corticobasal degeneration, and primary progressive aphasia [
         <a href="#rid223">
          223,224
         </a>
         ].
        </p>
        <p>
         Autopsy findings in patients with
         <em>
          LRRK2
         </em>
         -associated PD are heterogeneous and range from pure nigral degeneration without Lewy bodies to pathology consistent with typical PD, diffuse Lewy body disease, and neurofibrillary tangle and other tau pathology [
         <a href="#rid223">
          223,225,226
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          <i>
           PRKN
          </i>
          -associated PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PD due to biallelic parkin (
         <em>
          PRKN
         </em>
         ) pathogenic variants (PARK2) usually have a family history consistent with autosomal recessive inheritance. The disease is characterized by early onset of symptoms (before age 50), a slowly progressive course, a symmetric presentation at onset of parkinsonian signs and symptoms (unlike classic PD, which is asymmetric), and early dystonia and postural instability. Additional features include leg tremor, freezing, festination, retropulsion, hyperreflexia, sensory axonal neuropathy, and autonomic involvement [
         <a href="#rid227">
          227-230
         </a>
         ]. Dementia is uncommon [
         <a href="#rid231">
          231
         </a>
         ]. However, on an individual basis, patients with early-onset PD who have
         <em>
          PRKN
         </em>
         variants are clinically indistinguishable from those with early-onset PD who lack
         <em>
          PRKN
         </em>
         variants [
         <a href="#rid232">
          232
         </a>
         ].
        </p>
        <p>
         There is typically a good response to levodopa with early development of motor fluctuations and dyskinesia. Fluorodopa PET shows a marked reduction in the fluorodopa uptake, similar to idiopathic PD, but asymptomatic carriers may also have abnormal PET studies [
         <a href="#rid233">
          233
         </a>
         ].
        </p>
        <p>
         Parkin, the protein product of the
         <em>
          PRKN
         </em>
         gene, is expressed in the substantia nigra and other brain regions, as well as in Lewy bodies. Normal parkin strongly binds to microtubules and is involved in ubiquitination and subsequent degradation of certain proteins by proteasomes [
         <a href="#rid168">
          168,234
         </a>
         ]. However, mutated parkin protein loses this proteasome-enhancing activity, and the result is a hastening of neuronal cell death because the disabled proteasome cannot clear the cell of accumulating aggregated protein. Neurodegeneration associated with the parkin mutation is not usually accompanied by formation of Lewy bodies, although there are exceptions [
         <a href="#rid235">
          235
         </a>
         ].
        </p>
        <p>
         Over 180 variants and polymorphisms have been identified in the
         <em>
          PRKN
         </em>
         gene [
         <a href="#rid231">
          231
         </a>
         ]. However, it is not clear which of these changes leads to functional deficits. Several studies have demonstrated that heterozygous
         <em>
          PRKN
         </em>
         variants in the general population are
         <strong>
          not
         </strong>
         associated with increased risk of PD [
         <a href="#rid236">
          236-239
         </a>
         ].
        </p>
        <p>
         The incomplete penetrance and variability of clinical and pathologic expression of
         <em>
          PRKN
         </em>
         -associated PD may be due to an interaction between the
         <em>
          PRKN
         </em>
         gene and other genes, including
         <em>
          SNCA
         </em>
         [
         <a href="#rid240">
          240
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          <i>
           PINK1
          </i>
          -associated PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biallelic variants in the mitochondrial
         <em>
          PINK1
         </em>
         gene (PARK6) are associated with autosomal recessive familial PD. Most patients are younger than 50 years of age at onset, have a slowly progressive course, and have an excellent response to levodopa [
         <a href="#rid241">
          241-243
         </a>
         ], similar to patients with
         <em>
          PRKN
         </em>
         and
         <em>
          DJ-1
         </em>
         variants.
         <em>
          PINK1
         </em>
         variants have been found worldwide with a frequency that ranges from 1 to 8 percent of patients, most of whom had early-onset and/or familial PD [
         <a href="#rid179">
          179,242,244-246
         </a>
         ].
        </p>
        <p>
         Postmortem brain examinations of patients with
         <em>
          PINK1
         </em>
         -associated PD are limited to a few cases. One showed Lewy body pathology in the brainstem and Meynert nucleus, while the locus ceruleus and the amygdala were spared [
         <a href="#rid247">
          247
         </a>
         ]; another case revealed nigral degeneration without Lewy bodies [
         <a href="#rid248">
          248
         </a>
         ].
        </p>
        <p>
         <em>
          PINK1
         </em>
         variants may cause disease through a loss-of-function effect resulting in mitochondrial dysfunction [
         <a href="#rid249">
          249,250
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          <i>
           DJ-1
          </i>
          -associated PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biallelic variants in the mitochondrial
         <em>
          DJ-1
         </em>
         gene (PARK7) are associated with autosomal recessive inheritance, age younger than 40 at onset, slow progression, and good response to levodopa [
         <a href="#rid251">
          251,252
         </a>
         ]. Wildtype
         <em>
          DJ-1
         </em>
         is thought to be neuroprotective against oxidative stress.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional monogenic forms of parkinsonism are classified by the predominant phenotype and the specific gene variant [
         <a href="#rid174">
          174,175
         </a>
         ]. An updated list of genetically determined movement disorders is available on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.movementdisorders.org%2FMDS%2FAbout%2FCommittees--Other-Groups%2FStudy-Groups%2FGenetic-Nomenclature-in-Movement-Disorders.htm&amp;token=llmlCXD9pI7ITsnxPS6MizIWGoykRV8ebH1QMMg2dBpdHNcFVVKS0h%2BT0LRYJdXUoZl4LsqadBQQpnUyHmkSn81y8hQ3vJhV3BJp%2BsrFtN09Sb%2BK1uDgfLMBr541ih5gvJOv1EV8DsXyuKKGOHEh0Q%3D%3D&amp;TOPIC_ID=4906" target="_blank">
          International Parkinson and Movement Disorder Society (MDS)
         </a>
         website.
        </p>
        <p class="headingAnchor" id="H2768569153">
         <span class="h2">
          Risk alleles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous candidate risk alleles associated with increased risk of PD have been identified through GWAS and other population screening efforts. In addition to the gene discussed below, common variants in the
         <em>
          SNCA
         </em>
         gene may also function as risk alleles, distinct from rare, disease-causing variants. (See
         <a class="local">
          'SNCA-associated PD'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H918597100">
         <span class="h3">
          Glucocerebrosidase gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heterozygous pathogenic variants in the glucocerebrosidase 1 (
         <em>
          GBA1
         </em>
         ) gene, which when homozygous are the cause of Gaucher disease, are an important genetic risk factor for PD [
         <a href="#rid1">
          1,253-257
         </a>
         ].
        </p>
        <p>
         Across various populations, the risk of PD among
         <em>
          GBA1
         </em>
         variant carriers is increased two- to sevenfold over noncarriers [
         <a href="#rid253">
          253,258-261
         </a>
         ]. The estimated penetrance of heterozygous
         <em>
          GBA1
         </em>
         variants for PD over a lifetime varies fairly widely, from approximately 10 to 30 percent depending on the population studied [
         <a href="#rid262">
          262-266
         </a>
         ]. Genotype-phenotype relationships have not been well established, but
         <em>
          GBA1
         </em>
         variant carriers as a group appear to have more cognitive decline compared with patients with idiopathic PD.
        </p>
        <p>
         Alterations in
         <em>
          GBA1
         </em>
         were initially linked with PD and other movement disorders in people of Ashkenazi Jewish decent, who have an increased prevalence of
         <em>
          GBA1
         </em>
         pathogenic variants [
         <a href="#rid267">
          267
         </a>
         ]. One of the largest studies analyzed data from 16 centers around the world, including 5691 patients with PD and 4898 controls [
         <a href="#rid253">
          253
         </a>
         ]. All centers screened for two relatively frequent
         <em>
          GBA1
         </em>
         pathogenic variants (N370S and L444P). Compared with controls, either
         <em>
          GBA1
         </em>
         variant was more common in patients with PD, both among Ashkenazi Jewish subjects (15 percent, versus 3 percent of controls) and among non-Ashkenazi Jewish subjects (3 percent, versus &lt;1 percent of controls). Overall, the likelihood of finding any
         <em>
          GBA1
         </em>
         pathogenic variant was significantly higher in patients with PD than in controls (odds ratio 5.43, 95% CI 3.89-7.57).
        </p>
        <p>
         Among all patients with PD, the clinical profile was generally similar. However, when compared with patients who had PD but lacked a
         <em>
          GBA1
         </em>
         pathogenic variant, those with PD who carried a
         <em>
          GBA1
         </em>
         variant were significantly more likely to have the following features [
         <a href="#rid253">
          253
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Younger age at onset
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less prominent tremor, bradykinesia, and rigidity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower frequency of asymmetric onset
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher frequency of a family history of PD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater likelihood of cognitive impairment
        </p>
        <p>
        </p>
        <p>
         Other reports have also found that patients with PD who are
         <em>
          GBA1
         </em>
         pathogenic variant carriers have a younger age at onset, faster motor progression, and an increased prevalence of cognitive dysfunction compared with noncarriers [
         <a href="#rid267">
          267-273
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4203493518">
         <span class="h3">
          Other lysosomal genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is emerging evidence that variants in other lysosomal enzyme-encoding genes also affect PD risk through effects on alpha-synuclein [
         <a href="#rid274">
          274-278
         </a>
         ]. For example, several genetic variants in the sphingomyelin phosphodiesterase 1 (
         <em>
          SMPD1
         </em>
         )
         <em>
         </em>
         gene, the gene associated with Niemann-Pick type A, have been identified with increased prevalence in patients of Ashkenazi Jewish ancestry (and other populations) with PD compared with controls [
         <a href="#rid279">
          279-282
         </a>
         ]. Furthermore, experimentally,
         <em>
          SMPD1
         </em>
         knockdown results in alpha-synuclein accumulation [
         <a href="#rid279">
          279
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of clinical genetic testing in patients with PD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'Role of genetic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2161031852">
         <span class="h1">
          BIOMARKERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of a confirmatory diagnostic test, the clinical diagnosis of PD is made by history and neurologic examination, supplemented by striatal dopamine transporter imaging (DaTscan) in some cases. Structural MRI is used primarily to rule out rare, unexpected mimics of PD. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease"
         </a>
         .)
        </p>
        <p>
         There are a variety of biomarker techniques that are emerging as potential diagnostic tests for PD and other synucleinopathies. The two most investigated techniques are skin biopsy (using immunofluorescence to detect phosphorylated alpha-synuclein in skin nerve fibers) and alpha-synuclein seed amplification assays (SAAs; includes real-time quaking-induced conversion assay [RT-QuIC] and protein misfolding cyclic amplification [PMCA]) to identify abnormal clusters of alpha-synuclein in blood, cerebrospinal fluid (CSF), and/or skin [
         <a href="#rid283">
          283
         </a>
         ]. These tests have been found to have a high sensitivity and specificity for the diagnosis of alpha-synuclein neurodegenerative diseases including PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) [
         <a href="#rid284">
          284-287
         </a>
         ]. Some also show promise for distinguishing among PD and other synucleinopathies, but tests are not yet used for clinical diagnostic purposes.
        </p>
        <p class="headingAnchor" id="H20472691">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15524.html" rel="external">
          "Patient education: Parkinson disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/728.html" rel="external">
          "Patient education: Parkinson disease symptoms and diagnosis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2820612831">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132685.html" rel="external">
          "Patient perspective: Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Parkinson disease (PD) is one of the most common neurodegenerative diseases of adulthood and a major cause of neurologic morbidity and mortality worldwide. It is estimated to affect 0.3 percent of the adult population 40 years of age and older. (See
         <a class="local">
          'Incidence and prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incidence of PD rises steadily with age starting in the fifth decade and is higher in males, particularly between the ages of 50 and 60 years. Caffeine intake, physical activity, and cigarette smoking are consistently associated with lower risk of PD. Evidence linking PD with a variety of environmental exposures (eg, air pollution, pesticides, metals) is inconclusive. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="local">
          'Protective factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – The clinical features of PD (ie, bradykinesia, rigidity, and tremor) arise due to progressive degeneration of dopamine-producing neurons in the basal ganglia, including the substantia nigra in the midbrain  (
         <a class="graphic graphic_figure graphicRef82136" href="/z/d/graphic/82136.html" rel="external">
          figure 1
         </a>
         ). Dopamine depletion accounts for the emergence of the classic motor phenotype as well as a wide range of nonmotor and neuropsychiatric manifestations that affect function and quality of life. (See
         <a class="local">
          'Basal ganglia circuits'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic hallmarks
         </strong>
         – The brains of patients with PD show depigmentation (from loss of neuromelanin), neuronal loss, and gliosis, particularly in the substantia nigra pars compacta (SNc) and in the pontine locus ceruleus. These same areas are populated by Lewy bodies, which are round, eosinophilic, intracytoplasmic inclusions in the nuclei of neurons that stain positive for alpha-synuclein protein. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The precise mechanisms of neurodegeneration in PD are not yet understood, but they most likely involve a cascade of events that include interaction between genetic and environmental factors and abnormalities in protein processing, oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammation, immune regulation, and other mechanisms  (
         <a class="graphic graphic_figure graphicRef82386" href="/z/d/graphic/82386.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef72207" href="/z/d/graphic/72207.html" rel="external">
          figure 4
         </a>
         ). (See
         <a class="local">
          'Pathogenesis of cell degeneration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Although the majority of cases of PD appear to be sporadic, there are monogenic forms of parkinsonism (designated PARK1 through PARK23) related to nuclear and mitochondrial genes. (See
         <a class="local">
          'Monogenic forms of PD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Heterozygous pathogenic variants in the
         <em>
          GBA1
         </em>
         gene, which when homozygous are the cause of Gaucher disease, are the best characterized risk allele among patients with apparently sporadic PD. Other lysosomal genes have also been implicated as risk alleles. (See
         <a class="local">
          'Risk alleles'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020; 91:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord 1990; 5:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004; 75:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 2006; :9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014; 29:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rong S, Xu G, Liu B, et al. Trends in Mortality From Parkinson Disease in the United States, 1999-2019. Neurology 2021; 97:e1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pesce G, Artaud F, Roze E, et al. Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study. Brain 2023; 146:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006; 60:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigerio R, Sanft KR, Grossardt BR, et al. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord 2006; 21:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello S, Cockburn M, Bronstein J, et al. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firestone JA, Smith-Weller T, Franklin G, et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005; 62:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009; 66:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisskopf MG, Knekt P, O'Reilly EJ, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology 2010; 74:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013; 80:2035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jo S, Kim YJ, Park KW, et al. Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease. JAMA Neurol 2021; 78:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krzyzanowski B, Searles Nielsen S, Turner JR, Racette BA. Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries. Neurology 2023; 101:e2058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol 2014; 29:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016; 15:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010; 172:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman SM, Weaver FM, Stroupe KT, et al. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol 2023; 80:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 2002; 59:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers KM, Smith-Weller T, Franklin GM, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003; 60:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv Z, Qi H, Wang L, et al. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2014; 35:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Evatt ML, Maldonado LG, et al. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord 2015; 30:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrestha S, Lutsey PL, Alonso A, et al. Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk. Mov Disord 2016; 31:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 2005; 65:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beard JD, Steege AL, Ju J, et al. Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011. MMWR Morb Mortal Wkly Rep 2017; 66:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu G, Jousilahti P, Nissinen A, et al. Body mass index and the risk of Parkinson disease. Neurology 2006; 67:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nam GE, Kim SM, Han K, et al. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med 2018; 15:e1002640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Pablo-Fernandez E, Goldacre R, Pakpoor J, et al. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 2018; 91:e139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chohan H, Senkevich K, Patel RK, et al. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Mov Disord 2021; 36:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullinane PW, de Pablo Fernandez E, König A, et al. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts. Mov Disord 2023; 38:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord 2013; 28:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner RC, Burke JF, Nettiksimmons J, et al. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 2015; 77:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner RC, Byers AL, Barnes DE, et al. Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study. Neurology 2018; 90:e1771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76:2002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol 2012; 69:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One 2012; 7:e45183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inzelberg R, Flash S, Friedman E, Azizi E. Cutaneous malignant melanoma and Parkinson disease: Common pathways? Ann Neurol 2016; 80:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalvin LA, Damento GM, Yawn BP, et al. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc 2017; 92:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugier PE, Lucotte EA, Domenighetti C, et al. Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers. Mov Disord 2023; 38:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology 2015; 84:2422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen CC, Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology 2013; 81:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang F, Xu Q, Park Y, et al. Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study. Mov Disord 2010; 25:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob EL, Gatto NM, Thompson A, et al. Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord 2010; 16:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso A, Rodríguez LA, Logroscino G, Hernán MA. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry 2009; 80:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006; 113:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams-Carr KL, Bestwick JP, Shribman S, et al. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2016; 87:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012; 175:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mappin-Kasirer B, Pan H, Lewington S, et al. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology 2020; 94:e2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004; 27:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008; 14:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014; 83:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover S, Lill CM, Kasten M, et al. Risky behaviors and Parkinson disease: A mendelian randomization study. Neurology 2019; 93:e1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord 2012; 27:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa J, Lunet N, Santos C, et al. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010; 20 Suppl 1:S221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes KC, Gao X, Molsberry S, et al. Physical activity and prodromal features of Parkinson disease. Neurology 2019; 93:e2157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SY, Suh JH, Yang SN, et al. Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease. JAMA Neurol 2021; 78:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portugal B, Artaud F, Degaey I, et al. Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study. Neurology 2023; 101:e386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang X, Han D, Cheng Q, et al. Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2018; 1:e182421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 2011; :CD008454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai S, Song Y, Huang X, et al. Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis. PLoS One 2016; 11:e0152564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson's disease: A meta-analysis. Behav Brain Res 2016; 309:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bykov K, Yoshida K, Weisskopf MG, Gagne JJ. Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2017; 26:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu G, Sterling NW, Kong L, et al. Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. Mov Disord 2017; 32:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong SH, Lee HS, Chung SJ, et al. Effects of statins on dopamine loss and prognosis in Parkinson's disease. Brain 2021; 144:3191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens KN, Creanor S, Jeffery A, et al. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2022; 79:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CH, Chang CH, Tai CH, et al. A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. Mov Disord 2021; 36:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai R, Zhang Y, Simmering JE, et al. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest 2019; 129:4539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmering JE, Welsh MJ, Liu L, et al. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol 2021; 78:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease. Mov Disord 2022; 37:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. Nat Neurosci 2022; 25:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Perez AI, Sucunza D, Pedrosa MA, et al. Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death. Neurotherapeutics 2018; 15:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin HC, Tseng YF, Shen AL, et al. Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study. Am J Med 2022; 135:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jo Y, Kim S, Ye BS, et al. Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study. Front Pharmacol 2022; 13:837890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romanowska J, Bjornevik K, Cortese M, et al. Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study. Neurology 2023; 101:e2068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000; 23:S64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bamford NS, Robinson S, Palmiter RD, et al. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004; 24:9541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998; 13:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 2006; 21:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000; 23:S8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000; 23:S57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore H, Grace AA. A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies. Neuropsychopharmacology 2002; 27:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huot P, Lévesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007; 130:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huot P, Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 2007; 101:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003; 26:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128:2777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porritt M, Stanic D, Finkelstein D, et al. Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord 2005; 20:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 ( Pt 5):2283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakkenberg B, Møller A, Gundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991; 54:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centré median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camicioli R, Moore MM, Kinney A, et al. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami T, Shoji M, Imai Y, et al. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol 2004; 55:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000; 47:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007; 27:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004; 61:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014; 71:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodner RA, Outeiro TF, Altmann S, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 2006; 103:4246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012; 27:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calo L, Wegrzynowicz M, Santivañez-Perez J, Grazia Spillantini M. Synaptic failure and α-synuclein. Mov Disord 2016; 31:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maries E, Dass B, Collier TJ, et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003; 4:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feany MB. New genetic insights into Parkinson's disease. N Engl J Med 2004; 351:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meredith GE, Halliday GM, Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord 2004; 10:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehay B, Vila M, Bezard E, et al. Alpha-synuclein propagation: New insights from animal models. Mov Disord 2016; 31:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Pathogenesis-targeted therapeutic strategies in Parkinson's disease. Mov Disord 2019; 34:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE, Siderowf AD, Macklin EA, et al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med 2022; 387:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med 2022; 387:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vijayakumar D, Jankovic J. Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs 2022; 36:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol 2020; 19:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rietdijk CD, Perez-Pardo P, Garssen J, et al. Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol 2017; 8:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espay AJ, Vizcarra JA, Marsili L, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 2019; 92:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim KL, Zhang CW. Molecular events underlying Parkinson's disease - an interwoven tapestry. Front Neurol 2013; 4:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord 2013; 28:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014; 112:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xilouri M, Brekk OR, Stefanis L. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Mov Disord 2016; 31:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong H, Wang D, Chen L, et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usenovic M, Tresse E, Mazzulli JR, et al. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 2012; 32:4240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bové J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005; 2:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004; 36:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvaraj S, Sun Y, Watt JA, et al. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 2012; 122:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenamyre JT, Hastings TG. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science 2004; 304:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010; 75:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krantic S, Mechawar N, Reix S, Quirion R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci 2005; 28:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23:10756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006; 60:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005; 20:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 Suppl 1:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uehara T, Nakamura T, Yao D, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006; 441:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology 2009; 72:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68:1820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu W, Xie W, Pan T, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007; 21:3835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devos D, Labreuche J, Rascol O, et al. Trial of Deferiprone in Parkinson's Disease. N Engl J Med 2022; 387:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord 2013; 28:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yacoubian TA, Fang YD, Gerstenecker A, et al. Brain and Systemic Inflammation in De Novo Parkinson's Disease. Mov Disord 2023; 38:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang PF, Gao F. Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. J Neurol 2022; 269:2304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkin G, Paulson H. Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci 2014; 7:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131:1969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jellinger KA. Cell death mechanisms in Parkinson's disease. J Neural Transm (Vienna) 2000; 107:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003; 53 Suppl 3:S61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006; 12:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK. Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 2005; 113:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013; 28:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996; 47:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999; 281:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. Mov Disord 2022; 37:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord 2016; 31:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan MMX, Malek N, Lawton MA, et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 2019; 142:2828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010; 67:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg D, Schweitzer KJ, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 2005; 128:3000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007; 69:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996; 40:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostantjopoulou S, Katsarou Z, Papadimitriou A, et al. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 2001; 16:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018; 33:1857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006; 59:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singleton A, Gwinn-Hardy K, Sharabi Y, et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004; 127:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulman JM, De Jager PL. Evidence for a common pathway linking neurodegenerative diseases. Nat Genet 2009; 41:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pihlstrøm L, Blauwendraat C, Cappelletti C, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. Ann Neurol 2018; 84:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schapira AH. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 2006; 63:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whaley NR, Uitti RJ, Dickson DW, et al. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl 2006; :221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006; 251:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brice A. How much does dardarin contribute to Parkinson's disease? Lancet 2005; 365:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006; 67:1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farrer M, Stone J, Mata IF, et al. LRRK2 mutations in Parkinson disease. Neurology 2005; 65:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams-Gray CH, Goris A, Foltynie T, et al. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry 2006; 77:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesage S, Janin S, Lohmann E, et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 2007; 64:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Fonzo A, Rohé CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaig C, Ezquerra M, Marti MJ, et al. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007; 68:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedrich K, Winkler S, Hagenah J, et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 2006; 21:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay DM, Zabetian CP, Factor SA, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006; 21:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paisàn-Ruìz C, Sàenz A, Lòpez de Munain A, et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol 2005; 57:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-Asssociated Parkinson Disease Population. JAMA Neurol 2018; 75:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agalliu I, Ortega RA, Luciano MS, et al. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Mov Disord 2019; 34:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012; 78:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol 2015; 72:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warø BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease. Brain Behav 2018; 8:e00858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006; 59:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen-Plotkin AS, Yuan W, Anderson C, et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 2008; 70:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 2006; 67:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003; 54:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013; 70:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol 2013; 70:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohmann E, Thobois S, Lesage S, et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009; 72:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001; 49:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke RE. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 2004; 10:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007; 61:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langston JW, Tanner CM, Schüle B. Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol 2007; 61:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay DM, Stevens CF, Hamza TH, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu E, Rudakou U, Krohn L, et al. Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease. Mov Disord 2021; 36:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng H, Le WD, Hunter CB, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006; 63:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogaeva E, Johnson J, Lang AE, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61:1898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatano Y, Sato K, Elibol B, et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004; 63:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonifati V, Rohé CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishihara-Paul L, Hulihan MM, Kachergus J, et al. PINK1 mutations and parkinsonism. Neurology 2008; 71:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016; 86:2212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morais VA, Haddad D, Craessaerts K, et al. PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science 2014; 344:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 2013; 106-107:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003; 54:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 2014; 137:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizig M, Bandres-Ciga S, Makarious MB, et al. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol 2023; 22:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Heijer JM, Cullen VC, Quadri M, et al. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. Mov Disord 2020; 35:1667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan-Or Z, Amshalom I, Kilarski LL, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015; 84:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruskey JA, Greenbaum L, Roncière L, et al. Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. Eur J Med Genet 2019; 62:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestrino R, Tunesi S, Tesei S, et al. Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study. Mov Disord 2020; 35:2111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeill A, Duran R, Hughes DA, et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012; 83:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011; 46:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inzelberg R, Hassin-Baer S, Jankovic J. Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol 2014; 71:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013; 70:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mata IF, Leverenz JB, Weintraub D, et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 2016; 31:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol 2016; 80:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA-associated Parkinson's disease: The mutation matters. Ann Neurol 2016; 80:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maple-Grødem J, Dalen I, Tysnes OB, et al. Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology 2021; 96:e1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark LN, Chan R, Cheng R, et al. Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS One 2015; 10:e0125204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robak LA, Jansen IE, van Rooij J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain 2017; 140:3191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ysselstein D, Shulman JM, Krainc D. Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Mov Disord 2019; 34:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Kanai K, Suzuki M, et al. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain 2019; 142:2845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senkevich K, Beletskaia M, Dworkind A, et al. Association of Rare Variants in ARSA with Parkinson's Disease. Mov Disord 2023; 38:1806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay RN, Mallett V, Vanderperre B, et al. SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease. Mov Disord 2019; 34:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan E, Schlesinger I, Ayoub M, et al. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 2015; 21:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng S, Deng X, Song Z, et al. Systematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson's Disease. Mol Neurobiol 2016; 53:5025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan-Or Z, Orr-Urtreger A, Alcalay RN, et al. The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies. Parkinsonism Relat Disord 2015; 21:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellomo G, De Luca CMG, Paoletti FP, et al. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. Neurology 2022; 99:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mammana A, Baiardi S, Quadalti C, et al. RT-QuIC Detection of Pathological α-Synuclein in Skin Punches of Patients with Lewy Body Disease. Mov Disord 2021; 36:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donadio V, Wang Z, Incensi A, et al. In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC. Neurology 2021; 96:e2513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Valbuena I, Visanji NP, Olszewska DA, et al. Combining Skin α-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. Mov Disord 2022; 37:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 2023; 29:1448.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4906 Version 103.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32576618" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Parkinson's disease: etiopathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2404203" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15548480" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17017502" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The discovery of dopamine deficiency in the parkinsonian brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24976103" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The prevalence of Parkinson's disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287051" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16713924" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Epidemiology of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34706971" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Trends in Mortality From Parkinson Disease in the United States, 1999-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36415953" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23071076" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Meta-analysis of early nonmotor features and risk factors for Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16802290" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pesticide exposure and risk for Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16773614" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chemical exposures and Parkinson's disease: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19270050" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642854" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pesticides and risk of Parkinson disease: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19847896" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Professional exposure to pesticides and Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20350979" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Persistent organochlorine pesticides in serum and risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23713084" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Exposure to pesticides or solvents and risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33999109" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37903644" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24894826" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27751556" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The epidemiology of Parkinson's disease: risk factors and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20959505" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22083847" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Solvent exposures and Parkinson disease risk in twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37184848" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12433267" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Plantation work and risk of Parkinson disease in a population-based longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796527" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24847960" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Vitamin D status and Parkinson's disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25545356" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vitamin D from different sources is inversely associated with Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27090608" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16301484" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Education and occupations preceding Parkinson disease: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28704346" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17159100" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Body mass index and the risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30130376" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29898968" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33682937" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36567671" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609436" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Head injury and risk of Parkinson disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25726936" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Traumatic brain injury in later life increases risk for Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29669907" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21646627" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Meta-analysis of the relationship between Parkinson disease and melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22945795" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23028833" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27761938" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cutaneous malignant melanoma and Parkinson disease: Common pathways?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28688464" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Parkinson Disease and Melanoma: Confirming and Reexamining an Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36788297" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25995056" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Depression and subsequent risk of Parkinson disease: A nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24089392" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk of Parkinson disease after depression: a nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20310050" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20674460" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Occurrence of depression and anxiety prior to Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19448091" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Use of antidepressants and the risk of Parkinson's disease: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16542159" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A systematic review of depression and mental illness preceding Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26345189" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Constipation preceding Parkinson's disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20220126" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Smoking duration, intensity, and risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17620489" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pooled analysis of tobacco use and risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22505763" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Caffeine intake, smoking, and risk of Parkinson disease in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32371450" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15331239" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Smoking, nicotine and Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18332838" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impulse control disorders and pathological gambling in patients with Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25217056" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16484638" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31527283" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risky behaviors and Parkinson disease: A mendelian randomization study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22927157" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Caffeine and risk of Parkinson's disease in a large cohort of men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182023" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31719136" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Physical activity and prodromal features of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724534" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37197993" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646166" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19728750" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308684" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21368281" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Use of ibuprofen and risk of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071848" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27019096" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27131781" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Statin use and risk of Parkinson's disease: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27527987" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28370314" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34347020" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effects of statins on dopamine loss and prognosis in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36315128" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33449392" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31524631" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33523098" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Association of Glycolysis-Enhancingα-1 Blockers With Risk of Developing Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36054705" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35513515" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29987762" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35580718" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35308220" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37816645" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11052222" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Molecular effects of dopamine on striatal-projection pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509741" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Dopamine modulates release from corticostriatal terminals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9756147" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16830313" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Oscillations in the basal ganglia under normal conditions and in movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11052215" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Pathophysiology of the basal ganglia in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11052221" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Electrophysiology of dopamine in normal and denervated striatal neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12464455" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17142832" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17286588" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Dopaminergic neurons intrinsic to the striatum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12689773" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16081470" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15726582" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Dopaminergic innervation of the human striatum in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1933245" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Ageing and Parkinson's disease: substantia nigra regional selectivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2010756" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10716254" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Degeneration of the centrémedian-parafascicular complex in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12815657" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Parkinson's disease is associated with hippocampal atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14991825" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Pael-R is accumulated in Lewy bodies of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10762166" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Synphilin-1 is present in Lewy bodies in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18018486" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596612" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24514863" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Parkinson disease subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537516" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23183883" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : 100 years of Lewy pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474848" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Invited Article: Nervous system pathology in sporadic Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19067353" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A critical evaluation of the Braak staging scheme for Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22081500" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26790375" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Synaptic failure andα-synuclein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278044" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Alpha-synuclein in Lewy bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12951565" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : The role of alpha-synuclein in Parkinson's disease: insights from animal models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15525720" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : New genetic insights into Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120093" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12367530" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26347034" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Alpha-synuclein propagation: New insights from animal models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23161999" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Pathologicalα-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22508839" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Intracerebral inoculation of pathologicalα-synuclein initiates a rapidly progressive neurodegenerativeα-synucleinopathy in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391962" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391963" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30484897" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35921450" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Trial of Cinpanemab in Early Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35921451" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Trial of Prasinezumab in Early-Stage Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35212935" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32562684" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Safety and immunogenicity of theα-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28243222" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Exploring Braak's Hypothesis of Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30745444" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23580245" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Molecular events underlying Parkinson's disease - an interwoven tapestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23580333" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Lysosomal impairment in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24211851" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Autophagy and apoptosis dysfunction in neurodegenerative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26813776" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19229105" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22442086" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Deficiency of ATP13A2 leads to lysosomal dysfunction,α-synuclein accumulation, and neurotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389312" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Toxin-induced models of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15377875" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22446186" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2566813" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Mitochondrial complex I deficiency in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155938" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Biomedicine. Parkinson's--divergent causes, convergent mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21115957" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114629" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16216345" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Molecular basis of programmed cell death involved in neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645467" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Mechanism of toxicity in rotenone models of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16969854" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : A heterozygous effect for PINK1 mutations in Parkinson's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18093566" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Mitochondria in the aetiology and pathogenesis of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15580550" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15885630" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Neuroinflammatory processes in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16724068" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19380704" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Brain iron homeostasis and neurodegenerative disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17515544" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Individual dopaminergic neurons show raised iron levels in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22266337" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Iron dysregulation in movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22286308" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17690154" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36449420" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Trial of Deferiprone in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19296921" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Neuroinflammation in Parkinson's disease: a target for neuroprotection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22927094" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Pathogenesis of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104149" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36853618" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Brain and Systemic Inflammation in De Novo Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724571" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823471" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Diagnosis and treatment of Parkinson disease: molecules to medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372132" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : The progression of Parkinson disease: a hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25071440" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Ubiquitin pathways in neurodegenerative disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18187492" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809400" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Cell death mechanisms in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12666099" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Apoptosis in Parkinson's disease: signals for neuronal degradation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17079513" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Microtubule: a common target for parkin and Parkinson's disease toxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117171" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Mechanisms of Disease: astrocytes in neurodegenerative disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140639" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Developmental pesticide models of the Parkinson disease phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23389780" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : The genetics of Parkinson's disease: progress and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8710070" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Risk of Parkinson's disease among first-degree relatives: A community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9929087" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Parkinson disease in twins: an etiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35481685" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27079681" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31324919" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20837857" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251215" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761553" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9462735" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14755719" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8895469" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Mapping of a gene for Parkinson's disease to chromosome 4q21-q23.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197268" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8957018" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Clinical genetic analysis of Parkinson's disease in the Contursi kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11748731" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30357936" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16358335" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17251522" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14736756" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935760" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Evidence for a common pathway linking neurodegenerative diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896109" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19915576" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19915575" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Genome-wide association study reveals genetic risk underlying Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21292315" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30146727" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891824" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541308" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541309" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966498" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : The importance of LRRK2 mutations in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17017533" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17097110" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680438" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : How much does dardarin contribute to Parkinson's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16240353" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050822" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680457" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : A common LRRK2 mutation in idiopathic Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157908" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : LRRK2 mutations in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614029" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17353388" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18539534" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680455" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680456" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16533964" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436782" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215492" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16758483" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16250030" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15732106" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Familial Parkinson's disease: clinical and genetic analysis of four Basque families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29309488" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Progression in the LRRK2-Asssociated Parkinson Disease Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31348549" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323743" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25401981" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29568677" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16437559" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : Lrrk2 and Lewy body disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17914064" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060595" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25401511" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10824074" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : Association between early-onset Parkinson's disease and mutations in the parkin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891670" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : How much phenotypic variation can be attributed to parkin genotype?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12764051" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Parkin disease: a phenotypic study of a large case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23459986" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : Parkin disease: a clinicopathologic entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23835509" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Next-generation phenotyping using the parkin example: time to catch up with genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18987353" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11261512" id="rid232" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          233 : Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998437" id="rid233" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          234 : Recent advances in research on Parkinson disease: synuclein and parkin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16130111" id="rid234" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          235 : Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187375" id="rid235" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          236 : Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262853" id="rid236" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          237 : Parkin gene variations and parkinsonism: association does not imply causation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876472" id="rid237" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          238 : A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32970363" id="rid238" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          239 : Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476817" id="rid239" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          240 : Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087508" id="rid240" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          241 : Hereditary early-onset Parkinson's disease caused by mutations in PINK1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596610" id="rid241" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          242 : Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15349860" id="rid242" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          243 : PINK1 mutations are associated with sporadic early-onset parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505170" id="rid243" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          244 : PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009891" id="rid244" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          245 : Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18685134" id="rid245" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          246 : PINK1 mutations and parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20356854" id="rid246" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          247 : PINK1-linked parkinsonism is associated with Lewy body pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164705" id="rid247" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          248 : Absence of Lewy pathology associated with PINK1 homozygous mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24652937" id="rid248" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          249 : PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23643800" id="rid249" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          250 : Mitochondrial dysfunction and oxidative stress in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12446870" id="rid250" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          251 : Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891685" id="rid251" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          252 : Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846850" id="rid252" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          253 : Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734182" id="rid253" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          254 : GBA-associated PD presents with nonmotor characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23079555" id="rid254" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          255 : The link between the GBA gene and parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24477431" id="rid255" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          256 : Reduced glucocerebrosidase is associated with increasedα-synuclein in sporadic Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37633302" id="rid256" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          257 : Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32618053" id="rid257" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          258 : A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25653295" id="rid258" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          259 : Differential effects of severe vs mild GBA mutations on Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29842932" id="rid259" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          260 : Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947659" id="rid260" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          261 : Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32767585" id="rid261" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          262 : Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22282650" id="rid262" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          263 : Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24756352" id="rid263" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          264 : Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22577228" id="rid264" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          265 : A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21067946" id="rid265" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          266 : The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25347348" id="rid266" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          267 : Genetic movement disorders in patients of jewish ancestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22442429" id="rid267" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          268 : Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699752" id="rid268" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          269 : Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26296077" id="rid269" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          270 : GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27717005" id="rid270" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          271 : Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27632223" id="rid271" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          272 : Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33443131" id="rid272" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          273 : Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25933391" id="rid273" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          274 : Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29140481" id="rid274" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          275 : Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30726573" id="rid275" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          276 : Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31312839" id="rid276" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          277 : Arylsulfatase A, a genetic modifier of Parkinson's disease, is anα-synuclein chaperone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37381728" id="rid277" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          278 : Association of Rare Variants in ARSA with Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30788890" id="rid278" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          279 : SMPD1 mutations, activity, andα-synuclein accumulation in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26169695" id="rid279" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          280 : The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26377108" id="rid280" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          281 : Systematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320887" id="rid281" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          282 : The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35914941" id="rid282" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          283 : α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34002890" id="rid283" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          284 : RT-QuIC Detection of Pathologicalα-Synuclein in Skin Punches of Patients with Lewy Body Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33837116" id="rid284" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          285 : In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35019153" id="rid285" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          286 : Combining Skinα-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37248302" id="rid286" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          287 : Propagativeα-synuclein seeds as serum biomarkers for synucleinopathies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
